Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 611-618

  Ingham, Sarah L ^a,b   Sperrin, Matthew ^a   Baildam, Andrew ^c   Ross, Gary L ^d   Clayton, Richard ^e   Lalloo, Fiona ^e   Buchan, Iain ^a   Howell, Anthony ^b,f   Evans, D Gareth R ^b,e,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BRCA; Breast cancer; Surgery; Survival

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; FAMILY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MASTECTOMY; OVARY CANCER; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; RELATIVE; RISK REDUCING SURGERY; RISK REDUCTION; SURGERY; TUMOR SUPPRESSOR GENE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84890309562     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2765-x     Document Type: Article

References (28)

1. Schrag D, Kuntz KM, Garber JE, et al. (1997) Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336(20):1465-1471
2. Kurian AW, Munoz DF, Rust P, et al. (2012) An online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30(5):497-506
3. Sigal BM, Munoz DF, Kurian AW, et al. (2012) A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21(7):1066-1077
4. Byrd LM, Shenton A, Maher ER, et al. (2008) Better life expectancy in women with BRCA2 compared to BRCA1 mutations is attributable to lower frequency, later onset and better cure rates of ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(6):1535-1542
5. Domchek SM, Friebel TM, Singer CF, et al. (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967-975
6. Domchek S, Friebel-Klingner T, Neuhausen SL, et al. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223-229
7. Moller P, Borg A, Evans DG, et al. (2002) Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101(6):555-559
8. Rebbeck TR, Lynch HT, Neuhausen SL, et al. (2002) Prevention and observation of Surgical End Points Study Group. Reduction in cancer risk after bilateral prophylactic BSO in BRCA1 and BRCA2 mutation carriers. N Engl J Med 346:1616-1622
9. Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F (2009) Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 17(11):1381-1385
10. Evans DGR, Baildam AD, Anderson E, Brain A, Shenton A, Vasen HFA, Eccles D, Lucassen A, Pichert G, Hamed H, Moller P, Maehle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A (2009) Risk reducing mastectomy: outcomes in 10 European Centres. J Med Genet 46(4):254-258
11. R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical. Computing, Vienna, Austria. http://www.R-project.org/. Accessed 20 Sep 2013
12. Sperrin M, Buchan I (2003) Modelling time to event with observations made at arbitrary times. Stat Med 32(1):99-109
13. Smith A, Moran A, Boyd MC, et al. (2007) The trouble with phenocopies: are those testing negative for a family BRCA1/2 mutation really at population risk? J Med Genet 44(1):10-15
14. Evans DG, Shenton A, Woodward E, et al. (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1):155
15. Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526
16. Evans DG, Gaarenstroom KN, Stirling D, et al. (2009) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9):593-597
17. Passaperuma K, Warner E, Causer PA, et al. (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107(1):24-30
18. Chéreau E, Uzan C, Balleyguier C, et al. (2010) Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer 10(2):113-118
19. Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L (2013) Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat 139(1):155-161
20. Evans DG, Howell A (2012) Are we ready for online tools in decision making for BRCA1/2 mutation carriers? J Clin Oncol 30(5):471-473
21. Hagen AI, Kvistad KA, Maehle L, et al. (2007) Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367-374
22. Kriege M, Brekelmans CT, Peterse H, et al. (2007) Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 102:357-363
23. Kuhl CK, Schrading S, Leutner CC, et al. (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476
24. Leach MO, Boggis CR, Dixon AK, et al. (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778
25. Trecate G, Vergnaghi D, Bergonzi S, et al. (2003) Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: a preliminary experience. Tumori 89:125-131
26. Stirling D, Evans DG, Pichert G, et al. (2005) Familial ovarian cancer screening: current protocols are ineffective in detecting early stage ovarian malignancy. J Clin Oncol 23(24):5588-5596
27. Sidon L, Ingham S, Clancy T, et al. (2012) Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br J Cancer 106(4):775-779
28. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A (2009) Uptake of risk reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age and time dependent. Cancer Epidemiol Biomarkers Prev 18(8):2318-2324